Russell Investments Group
TARS icon

Russell Investments Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Russell Investments Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.63M Sell
89,526
-56,400
-39% -$3.6M ﹤0.01% 1432
2026
Q1 		$10.2M Sell
145,926
-7,834
-5% -$547K 0.01% 928
2025
Q4 		$12.6M Buy
153,760
+5,431
+4% +$406K 0.01% 799
2025
Q3 		$8.82M Buy
148,329
+3,089
+2% +$152K 0.01% 969
2025
Q2 		$5.88M Buy
145,240
+10,623
+8% +$478K 0.01% 1109
2025
Q1 		$6.92M Buy
134,617
+132,450
+6,112% +$6.55M 0.01% 991
2024
Q4 		$120K Buy
2,167
+56
+3% +$2.54K ﹤0.01% 2653
2024
Q3 		$69.4K Sell
2,111
-73,765
-97% -$2.07M ﹤0.01% 2723
2024
Q2 		$2.06M Buy
75,876
+45,840
+153% +$1.54M ﹤0.01% 1623
2024
Q1 		$1.09M Buy
30,036
+29,959
+38,908% +$881K ﹤0.01% 1944
2023
Q4 		$1.56K Buy
77
+52
+208% +$868 ﹤0.01% 3026
2023
Q3 		$444 Hold
25
– – ﹤0.01% 3417
2023
Q2 		$452 Hold
25
– – ﹤0.01% 3367
2023
Q1 		$314 Buy
+25
New +$366 ﹤0.01% 3223

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Russell Investments Group's TARS Position: Q2 2026 in Review

Russell Investments Group reduced its Tarsus Pharmaceuticals (TARS) stake by 39% in Q2 2026, selling an estimated $3.6M and leaving 89,526 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Russell Investments Group first reported a position in TARS in Q1 2023 and has held it in 14 quarters since. The position peaked at $12.6M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Russell Investments Group held 89,526 shares of Tarsus Pharmaceuticals worth $5.63M as of Q2 2026.
  • Russell Investments Group sold 56,400 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.6M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1432 holding.
  • Russell Investments Group first reported a position in Tarsus Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Russell Investments Group's Tarsus Pharmaceuticals position peaked at $12.6M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.